Leerink Partnrs Increases Earnings Estimates for Certara

Certara, Inc. (NASDAQ:CERT) – Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Certara in a report issued on Wednesday, January 15th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.29 per share for the year, up from their prior estimate of $0.28. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

Several other brokerages have also weighed in on CERT. Robert W. Baird decreased their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Finally, Barclays cut their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.92.

Certara Price Performance

Shares of CERT stock opened at $11.76 on Friday. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a market capitalization of $1.89 billion, a P/E ratio of -58.80, a P/E/G ratio of 4.55 and a beta of 1.52. The stock has a 50 day moving average of $10.88 and a two-hundred day moving average of $11.95. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company’s revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.06 EPS.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Blue Trust Inc. raised its stake in shares of Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after buying an additional 2,076 shares during the last quarter. KBC Group NV boosted its position in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after purchasing an additional 6,868 shares during the last quarter. Intech Investment Management LLC bought a new stake in Certara in the second quarter valued at about $152,000. Finally, Algert Global LLC acquired a new position in Certara in the second quarter valued at about $156,000. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.